Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Preferred Stock Liabilities: 2020-2024

Historic Preferred Stock Liabilities for Pharming Group N.V (PHAR) over the last 5 years, with Dec 2024 value amounting to $82.4 million.

  • Pharming Group N.V's Preferred Stock Liabilities rose 6.52% to $96.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $96.4 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $82.4 million for FY2024, which is 40.47% down from last year.
  • Pharming Group N.V's Preferred Stock Liabilities amounted to $82.4 million in FY2024, which was down 40.47% from $138.4 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Preferred Stock Liabilities registered a high of $151.8 million during FY2020, and its lowest value of $82.4 million during FY2024.
  • For the 3-year period, Pharming Group N.V's Preferred Stock Liabilities averaged around $118.1 million, with its median value being $133.4 million (2022).
  • As far as peak fluctuations go, Pharming Group N.V's Preferred Stock Liabilities increased by 3.78% in 2023, and later plummeted by 40.47% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Preferred Stock Liabilities stood at $151.8 million in 2020, then decreased by 7.17% to $140.9 million in 2021, then fell by 5.32% to $133.4 million in 2022, then increased by 3.78% to $138.4 million in 2023, then crashed by 40.47% to $82.4 million in 2024.